Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Supernus Pharmaceuticals, Inc. on May 19, 2016. The record date for voting was March 22, 2016, with 49,407,236 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The following proposals were voted upon by stockholders:
- Proposal 1 (Election of Class I Directors):
- Jack A. Khattar: Elected (35,681,511 For; 768,112 Withheld).
- M. James Barrett, Ph.D.: Not Elected (13,329,960 For; 23,119,663 Withheld).
- William A. Nuerge: Elected (35,569,357 For; 880,266 Withheld).
- Proposal 2 (Ratification of Equity Incentive Plan Amendment): Failed to pass (19,834,525 For; 16,005,650 Against).
- Proposal 3 (Ratification of Employee Stock Purchase Plan Amendment): Passed (35,504,333 For; 347,000 Against).
- Proposal 4 (Ratification of Independent Auditor): Passed (36,810,937 For; 5,523 Against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the implications of the failed election of director M. James Barrett, Ph.D., given the significant number of votes withheld.
- Confirm the status of the Second Amended and Restated 2012 Equity Incentive Plan following the failure of Proposal 2.
- Review the definitive proxy statement filed on April 19, 2016, for detailed rationale behind the voting proposals.